Lehr Martin A. 4/A
4/A · Context Therapeutics Inc. · Filed Dec 17, 2021
Insider Transaction Report
Form 4/AAmended
Lehr Martin A.
DirectorChief Executive Officer
Transactions
- Conversion
Series Seed Preferred Stock
2021-10-22−586,475→ 1 total(indirect: By Trust)→ Common Stock (586,475 underlying) - Purchase
Common Stock
2021-10-22$5.00/sh+10,000$50,000→ 807,190 total(indirect: By Trust) - Exercise Out-of-Money
Warrant (right to buy)
2021-10-22+52,680→ 0 total(indirect: By Trust)Exercise: $7.14From: 2020-12-20Exp: 2030-12-20→ Common Stock (52,680 underlying) - Exercise Out-of-Money
Common Stock
2021-10-22$7.14/sh+52,680$376,135→ 0 total(indirect: By Trust) - Conversion
Common Stock
2021-10-22+210,715→ 210,715 total(indirect: By Trust) - Conversion
Common Stock
2021-10-22+586,475→ 797,190 total(indirect: By Trust) - Conversion
Series A Preferred Stock
2021-10-22−210,715→ 7 total(indirect: By Trust)→ Common Stock (210,715 underlying)
Holdings
- 89,583
Common Stock
Footnotes (3)
- [F1]Each share of Series A Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering.
- [F2]Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering.
- [F3]Fully vested.